<DOC>
	<DOCNO>NCT01490632</DOCNO>
	<brief_summary>This dose-ranging study design investigate efficacy safety LY3009104 treatment participant moderate severe , chronic plaque psoriasis assess Psoriasis Area Severity Index ( PASI ) score routine safety assessment .</brief_summary>
	<brief_title>A Phase 2b Study LY3009104 Participants With Moderate Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Skin Diseases , Papulosquamous</mesh_term>
	<criteria>You must active chronic plaque psoriasis least 6 month prior entry study You candidate systemic therapy and/or phototherapy You must active plaque psoriasis cover least 12 % body surface area You must Psoriasis Area Severity Index ( PASI ) score least 12 You must Static Physician 's Global Assessment ( sPGA ) score least 3 You must receive biologic agent/monoclonal antibody within 8 week prior entry study You must prior treatment oral Janus kinase ( JAK ) inhibitor You must receive systemic psoriasis ( Ps ) therapy within 4 week prior entry study You must receive phototherapy within 4 week prior entry study You must receive topical Ps therapy psoralens within 4 week prior entry study You must pregnant nursing If female childbearing potential male , agree use 2 form highly effective method birth control least 28 day follow last dose investigational product You must symptomatic herpes zoster herpes simplex infection within 12 week history disseminated/complicated herpes zoster You must evidence active infection , fever ≥38.0ºC ( 100.4ºF ) You must history active hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) You must immunocompromised , opinion investigator , unacceptable risk participate study You must know history hypogammaglobulinemia You must serious systemic local infection within 12 week prior entry study You must expose live vaccine within 12 week prior entry study , expect need/receive live vaccine ( include herpes zoster vaccination ) course study You must household contact person active tuberculosis ( TB ) receive appropriate document prophylaxis TB You must serious and/or unstable illness , opinion investigator , pose unacceptable risk participation study You must history lymphoproliferative disease ; sign symptom suggestive possible lymphoproliferative disease , include lymphadenopathy splenomegaly ; active primary recurrent malignant disease ; remission clinically significant malignancy le 5 year You must history chronic alcohol abuse intravenous ( IV ) drug abuse within last 2 year You must donate blood 500 mL within 4 week You must receive topical Ps treatment within 2 week prior entry study Exceptions : class 6 ( mild , desonide ) class 7 ( least potent , hydrocortisone ) topical steroid use face , axilla , palm , sol , and/or genitalia nonmedicated shampoo ( example , contain corticosteroid , coal tar , vitamin D3 analogue ) emollient contain alpha beta hydroxyl acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Moderate</keyword>
	<keyword>Severe</keyword>
	<keyword>Plaque</keyword>
	<keyword>Chronic</keyword>
</DOC>